Literature DB >> 22293174

Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors.

Hélène Salmon1, Katarzyna Franciszkiewicz, Diane Damotte, Marie-Caroline Dieu-Nosjean, Pierre Validire, Alain Trautmann, Fathia Mami-Chouaib, Emmanuel Donnadieu.   

Abstract

Appropriate localization and migration of T cells is a prerequisite for antitumor immune surveillance. Studies using fixed tumor samples from human patients have shown that T cells accumulate more efficiently in the stroma than in tumor islets, but the mechanisms by which this occurs are unknown. By combining immunostaining and real-time imaging in viable slices of human lung tumors, we revealed that the density and the orientation of the stromal extracellular matrix likely play key roles in controlling the migration of T cells. Active T cell motility, dependent on chemokines but not on β1 or β2 integrins, was observed in loose fibronectin and collagen regions, whereas T cells migrated poorly in dense matrix areas. Aligned fibers in perivascular regions and around tumor epithelial cell regions dictated the migratory trajectory of T cells and restricted them from entering tumor islets. Consistently, matrix reduction with collagenase increased the ability of T cells to contact cancer cells. Thus, the stromal extracellular matrix influences antitumor immunity by controlling the positioning and migration of T cells. Understanding the mechanisms by which this collagen network is generated has the potential to aid in the development of new therapeutics.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22293174      PMCID: PMC3287213          DOI: 10.1172/JCI45817

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  42 in total

Review 1.  Immune resistance orchestrated by the tumor microenvironment.

Authors:  Thomas F Gajewski; Yuru Meng; Christian Blank; Ian Brown; Aalok Kacha; Justin Kline; Helena Harlin
Journal:  Immunol Rev       Date:  2006-10       Impact factor: 12.988

2.  In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor.

Authors:  Alexandre Boissonnas; Luc Fetler; Ingrid S Zeelenberg; Stéphanie Hugues; Sebastian Amigorena
Journal:  J Exp Med       Date:  2007-01-29       Impact factor: 14.307

3.  Requirements for T lymphocyte migration in explanted lymph nodes.

Authors:  Julie H Huang; L Isabel Cárdenas-Navia; Charles C Caldwell; Troy J Plumb; Caius G Radu; Paulo N Rocha; Tuere Wilder; Jonathan S Bromberg; Bruce N Cronstein; Michail Sitkovsky; Mark W Dewhirst; Michael L Dustin
Journal:  J Immunol       Date:  2007-06-15       Impact factor: 5.422

4.  Functional CD8+ T cells infiltrate into nonsmall cell lung carcinoma.

Authors:  Elizabeth M E Verdegaal; Conny Hoogstraten; Maro H Sandel; Peter J K Kuppen; Antoinette A T P Brink; Frans H J Claas; Michael C B Gorsira; J Frans Graadt van Roggen; Susanne Osanto
Journal:  Cancer Immunol Immunother       Date:  2006-08-22       Impact factor: 6.968

Review 5.  Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer.

Authors:  Haruo Ohtani
Journal:  Cancer Immun       Date:  2007-02-21

6.  Tumor immune escape by the loss of homeostatic chemokine expression.

Authors:  Andor Pivarcsi; Anja Müller; Andreas Hippe; Juliane Rieker; Anke van Lierop; Martin Steinhoff; Stephan Seeliger; Robert Kubitza; Ulrich Pippirs; Stephan Meller; Peter A Gerber; Ruediger Liersch; Erich Buenemann; Eniko Sonkoly; Ulrike Wiesner; Thomas K Hoffmann; Leonid Schneider; Roland Piekorz; Elaine Enderlein; Julia Reifenberger; Ulrich-Peter Rohr; Rainer Haas; Petra Boukamp; Ingo Haase; Bernd Nürnberg; Thomas Ruzicka; Albert Zlotnik; Bernhard Homey
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-19       Impact factor: 11.205

7.  High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer.

Authors:  Shozo Hojo; Keiichi Koizumi; Koichi Tsuneyama; Yoshihisa Arita; Zhengguo Cui; Kanna Shinohara; Takayuki Minami; Isaya Hashimoto; Takashi Nakayama; Hiroaki Sakurai; Yasuo Takano; Osamu Yoshie; Kazuhiro Tsukada; Ikuo Saiki
Journal:  Cancer Res       Date:  2007-05-15       Impact factor: 12.701

8.  Collagen reorganization at the tumor-stromal interface facilitates local invasion.

Authors:  Paolo P Provenzano; Kevin W Eliceiri; Jay M Campbell; David R Inman; John G White; Patricia J Keely
Journal:  BMC Med       Date:  2006-12-26       Impact factor: 8.775

9.  Random migration precedes stable target cell interactions of tumor-infiltrating T cells.

Authors:  Paulus Mrass; Hajime Takano; Lai Guan Ng; Sachin Daxini; Marcio O Lasaro; Amaya Iparraguirre; Lois L Cavanagh; Ulrich H von Andrian; Hildegund C J Ertl; Philip G Haydon; Wolfgang Weninger
Journal:  J Exp Med       Date:  2006-11-20       Impact factor: 14.307

10.  CCR7 ligands control basal T cell motility within lymph node slices in a phosphoinositide 3-kinase-independent manner.

Authors:  François Asperti-Boursin; Eliana Real; Georges Bismuth; Alain Trautmann; Emmanuel Donnadieu
Journal:  J Exp Med       Date:  2007-05-07       Impact factor: 14.307

View more
  286 in total

1.  Recurrence of melanoma following T cell treatment: continued antigen expression in a tumor that evades T cell recruitment.

Authors:  Trudy Straetemans; Cor Berrevoets; Miriam Coccoris; Elike Treffers-Westerlaken; Rebecca Wijers; David K Cole; Valerie Dardalhon; Andrew K Sewell; Naomi Taylor; Jaap Verweij; Reno Debets
Journal:  Mol Ther       Date:  2014-11-03       Impact factor: 11.454

Review 2.  Delivery of cancer therapeutics to extracellular and intracellular targets: Determinants, barriers, challenges and opportunities.

Authors:  Jessie L-S Au; Bertrand Z Yeung; Michael G Wientjes; Ze Lu; M Guillaume Wientjes
Journal:  Adv Drug Deliv Rev       Date:  2015-12-11       Impact factor: 15.470

Review 3.  Chemokine signaling in cancer-stroma communications.

Authors:  Arun J Singh; Joe W Gray
Journal:  J Cell Commun Signal       Date:  2021-06-04       Impact factor: 5.782

Review 4.  Fibroblasts and the ground they walk on.

Authors:  Daniel J Tschumperlin
Journal:  Physiology (Bethesda)       Date:  2013-11

Review 5.  Targeting the tumour stroma to improve cancer therapy.

Authors:  Kenneth C Valkenburg; Amber E de Groot; Kenneth J Pienta
Journal:  Nat Rev Clin Oncol       Date:  2018-06       Impact factor: 66.675

6.  Probing cellular response to topography in three dimensions.

Authors:  Colin D Paul; Alex Hruska; Jack R Staunton; Hannah A Burr; Kathryn M Daly; Jiyun Kim; Nancy Jiang; Kandice Tanner
Journal:  Biomaterials       Date:  2019-01-08       Impact factor: 12.479

7.  Fucosylation Enhances the Efficacy of Adoptively Transferred Antigen-Specific Cytotoxic T Lymphocytes.

Authors:  Na Qiao; Mao Zhang; Gheath Alatrash; Madhushree Zope; Alexander A Perakis; Pariya Sukhumalchandra; Anne V Philips; Haven R Garber; Celine Kerros; Lisa S St John; Maria R Khouri; Hiep Khong; Karen Clise-Dwyer; Leonard P Miller; Steve Wolpe; Willem W Overwijk; Jeffrey J Molldrem; Qing Ma; Elizabeth J Shpall; Elizabeth A Mittendorf
Journal:  Clin Cancer Res       Date:  2019-01-15       Impact factor: 12.531

8.  LW106, a novel indoleamine 2,3-dioxygenase 1 inhibitor, suppresses tumour progression by limiting stroma-immune crosstalk and cancer stem cell enrichment in tumour micro-environment.

Authors:  Rong Fu; Yi-Wei Zhang; Hong-Mei Li; Wen-Cong Lv; Li Zhao; Qing-Long Guo; Tao Lu; Stephen J Weiss; Zhi-Yu Li; Zhao-Qiu Wu
Journal:  Br J Pharmacol       Date:  2018-06-03       Impact factor: 8.739

Review 9.  Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.

Authors:  Thomas Shum; Robert L Kruse; Cliona M Rooney
Journal:  Expert Opin Biol Ther       Date:  2018-05-14       Impact factor: 4.388

Review 10.  Innate and adaptive immune cells in the tumor microenvironment.

Authors:  Thomas F Gajewski; Hans Schreiber; Yang-Xin Fu
Journal:  Nat Immunol       Date:  2013-10       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.